Pfizer (PFE) Stock Forecast & Price Target

$24.10 +0.17 (+0.69%)

As of 10:42 AM Eastern

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
1

Hold
8

Buy
6

Based on 15 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 8 have given a hold rating, 3 have given a buy rating, and 3 have given a strong buy rating for PFE.

Consensus Price Target

$29.17
21.04% Upside

According to the 15 analysts' twelve-month price targets for Pfizer, the average price target is $29.17. The highest price target for PFE is $34.00, while the lowest price target for PFE is $24.00. The average price target represents a forecasted upside of 21.04% from the current price of $24.10.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 5/2/24 to 5/2/25	1 Month Ago 4/2/24 to 4/2/25	3 Months Ago 2/2/24 to 2/1/25	1 Year Ago 5/3/23 to 5/2/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)	10 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$29.17	$31.92	$31.92	$36.00
Forecasted Upside	21.04% Upside	29.09% Upside	20.44% Upside	29.96% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	23.99% Upside	3,373.20% Upside	19.83% Upside
News Sentiment Rating	Positive News See Recent PFE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/30/2025	UBS Group 3 of 5 stars	Trung Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$24.00 ➝ $25.00	+3.55%
4/22/2025	Cantor Fitzgerald 3 of 5 stars	Carter Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00	+8.74%
4/8/2025	The Goldman Sachs Group 3 of 5 stars	Asad Haider Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$32.00 ➝ $25.00	+13.00%
3/27/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral
3/18/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$36.00 ➝ $32.00	+21.72%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$29.00	+11.03%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$25.00	-3.92%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$32.00	+7.89%
8/7/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:29 AM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 29, 2025. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

The current stock price is around $24.00, which is considered attractive by some analysts, suggesting potential for growth.
Pfizer Inc. recently reported earnings per share of $0.92, exceeding analysts' expectations, indicating strong financial performance.
The company has a consensus rating of "Moderate Buy" from analysts, reflecting overall positive sentiment towards its future prospects.
Pfizer Inc. has announced a quarterly dividend of $0.43, providing a yield of approximately 7.47%, which can be appealing for income-focused investors.
Recent insider buying activity, with a director acquiring a significant number of shares, may signal confidence in the company's future performance.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Analysts have issued several neutral ratings, indicating a lack of strong bullish sentiment and potential concerns about future growth.
The company's dividend payout ratio is currently over 121%, suggesting that it may be paying out more in dividends than it earns, which could be unsustainable.
Some analysts have reduced their price targets for Pfizer Inc., indicating a cautious outlook on the stock's performance.
There is a significant portion of analysts who have rated the stock as a hold, which may suggest uncertainty about its future direction.
Market conditions and competition in the biopharmaceutical sector can pose risks to Pfizer Inc.'s market position and profitability.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $29.17, with a high forecast of $34.00 and a low forecast of $24.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 3 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PFE shares.
: According to analysts, Pfizer's stock has a predicted upside of 21.04% based on their 12-month stock forecasts.
: Over the previous 90 days, Pfizer's stock had 1 upgrade by analysts.
: Pfizer has been rated by research analysts at Cantor Fitzgerald, Citigroup, Guggenheim, Hsbc Global Res, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.53 while the average consensus rating score for "medical" companies is 2.81. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:PFE) was last updated on 5/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Stock Forecast & Price Target